PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects.
Tsubaki M, Takeda T, Tani T, Shimaoka H, Suzuyama N, Sakamoto K, Fujita A, Ogawa N, Itoh T, Imano M, Funakami Y, Ichida S, Satou T, Nishida S.
Tsubaki M, et al. Among authors: takeda t.
Int J Cancer. 2015 Jul 1;137(1):243-50. doi: 10.1002/ijc.29367. Epub 2014 Dec 8.
Int J Cancer. 2015.
PMID: 25430564
Free article.